Home Featured Page 281

Featured

Latest

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Noetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector

Tryp Therapeutics Announces Application to List on OTCQB

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the...

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the...

PsyBio Therapeutics Announces Retention of Market Maker

PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins...

Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics...

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain...

atai Life Sciences Announces the Closing of its $157 Million Series...

Cybin Inc. Announces Uplisting to OTCQB Venture Market

1...280281282...304 Page 281 of 304

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Noetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector

Tryp Therapeutics Announces Application to List on OTCQB

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the...

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the...

PsyBio Therapeutics Announces Retention of Market Maker

PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins...

Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics...

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain...

atai Life Sciences Announces the Closing of its $157 Million Series...

Cybin Inc. Announces Uplisting to OTCQB Venture Market

EDITOR PICKS

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY